Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus

Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review

(2018) Soheil Tavakolpour et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials

(2017) Yue Han et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

(2017) Pascal Joly et al.   LANCET

Interleukin 4 inhibition as a potential therapeutic in pemphigus

(2016) Soheil Tavakolpour et al.   CYTOKINE

Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus

(2016) Soheil Tavakolpour   Dermatologic Therapy

Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study

(2016) VinodKumar Sharma et al.   Indian Journal of Dermatology Venereology & Leprology

Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?

(2016) Soheil Tavakolpour   INTERNATIONAL IMMUNOPHARMACOLOGY

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases

(2013) Hai-Feng Pan et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Interleukin-7: Fuel for the autoimmune attack

(2013) Hans Dooms   JOURNAL OF AUTOIMMUNITY